Does the media refer more to STEX or BWAY?

In the previous week, Brainsway had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Brainsway and 2 mentions for Biosig Technologies. Brainsway's average media sentiment score of 1.16 beat Biosig Technologies' score of 0.47 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STEX or NPCE?

In the previous week, Biosig Technologies and Biosig Technologies both had 2 articles in the media. NeuroPace's average media sentiment score of 1.57 beat Biosig Technologies' score of 0.47 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroPace 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor STEX or CLPT?

In the previous week, ClearPoint Neuro had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for ClearPoint Neuro and 2 mentions for Biosig Technologies. ClearPoint Neuro's average media sentiment score of 0.57 beat Biosig Technologies' score of 0.47 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ClearPoint Neuro 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STEX or SI?

In the previous week, Shoulder Innovations had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Shoulder Innovations and 2 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.47 beat Shoulder Innovations' score of 0.41 indicating that Biosig Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biosig Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shoulder Innovations 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biosig Technologies (STEX) Competitors

$0.97 -0.10 (-9.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.99 +0.02 (+1.99%)

As of 07:33 PM Eastern

Compare

STEX vs. BWAY, NPCE, CLPT, KIDS, and SI

Should you buy Biosig Technologies stock or one of its competitors? MarketBeat compares Biosig Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biosig Technologies include Brainsway (BWAY), NeuroPace (NPCE), ClearPoint Neuro (CLPT), OrthoPediatrics (KIDS), and Shoulder Innovations (SI). These companies are all part of the "medical equipment" industry.

How does Biosig Technologies compare to Brainsway?

Biosig Technologies (NASDAQ:STEX) and Brainsway (NASDAQ:BWAY) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Brainsway had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Brainsway and 2 mentions for Biosig Technologies. Brainsway's average media sentiment score of 1.16 beat Biosig Technologies' score of 0.47 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Brainsway has a net margin of 15.68% compared to Biosig Technologies' net margin of 0.00%. Brainsway's return on equity of 12.28% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Brainsway	15.68%	12.28%	7.75%

Brainsway has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,411.83	-$462.77M	-$9.71	N/A
Brainsway	$52.22M	11.67	$7.57M	$0.35	43.40

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 724.15%. Brainsway has a consensus target price of $16.00, indicating a potential upside of 5.33%. Given Biosig Technologies' higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Biosig Technologies has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Summary

Brainsway beats Biosig Technologies on 12 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to NeuroPace?

Biosig Technologies (NASDAQ:STEX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 724.15%. NeuroPace has a consensus target price of $18.83, indicating a potential upside of 16.69%. Given Biosig Technologies' higher probable upside, research analysts plainly believe Biosig Technologies is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Biosig Technologies has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
NeuroPace	-21.67%	-108.20%	-18.50%

NeuroPace has higher revenue and earnings than Biosig Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,411.83	-$462.77M	-$9.71	N/A
NeuroPace	$99.99M	5.50	-$21.47M	-$0.65	N/A

In the previous week, Biosig Technologies and Biosig Technologies both had 2 articles in the media. NeuroPace's average media sentiment score of 1.57 beat Biosig Technologies' score of 0.47 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biosig Technologies has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NeuroPace beats Biosig Technologies on 10 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to ClearPoint Neuro?

Biosig Technologies (NASDAQ:STEX) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, ClearPoint Neuro had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for ClearPoint Neuro and 2 mentions for Biosig Technologies. ClearPoint Neuro's average media sentiment score of 0.57 beat Biosig Technologies' score of 0.47 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearPoint Neuro	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biosig Technologies currently has a consensus price target of $8.00, suggesting a potential upside of 724.15%. ClearPoint Neuro has a consensus price target of $23.00, suggesting a potential upside of 22.86%. Given Biosig Technologies' higher probable upside, analysts clearly believe Biosig Technologies is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Biosig Technologies has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biosig Technologies has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. ClearPoint Neuro's return on equity of -140.96% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

ClearPoint Neuro has higher revenue and earnings than Biosig Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,411.83	-$462.77M	-$9.71	N/A
ClearPoint Neuro	$36.97M	15.19	-$25.54M	-$1.01	N/A

Summary

ClearPoint Neuro beats Biosig Technologies on 10 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to OrthoPediatrics?

Biosig Technologies (NASDAQ:STEX) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Biosig Technologies currently has a consensus price target of $8.00, indicating a potential upside of 724.15%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 22.53%. Given Biosig Technologies' higher probable upside, equities analysts plainly believe Biosig Technologies is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Biosig Technologies had 2 more articles in the media than OrthoPediatrics. MarketBeat recorded 2 mentions for Biosig Technologies and 0 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat Biosig Technologies' score of 0.47 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Neutral
OrthoPediatrics	Positive

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biosig Technologies has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

OrthoPediatrics has higher revenue and earnings than Biosig Technologies. OrthoPediatrics is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,411.83	-$462.77M	-$9.71	N/A
OrthoPediatrics	$236.35M	2.17	-$39.65M	-$1.68	N/A

Biosig Technologies has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

Summary

OrthoPediatrics beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to Shoulder Innovations?

Biosig Technologies (NASDAQ:STEX) and Shoulder Innovations (NYSE:SI) are both small-cap surgical, medical, and dental instruments and supplies industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Biosig Technologies has a net margin of 0.00% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -35.11% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Shoulder Innovations	-81.78%	-35.11%	-20.58%

7.2% of Biosig Technologies shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biosig Technologies presently has a consensus target price of $8.00, suggesting a potential upside of 724.15%. Shoulder Innovations has a consensus target price of $21.00, suggesting a potential downside of 0.74%. Given Biosig Technologies' higher possible upside, research analysts clearly believe Biosig Technologies is more favorable than Shoulder Innovations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Shoulder Innovations has higher revenue and earnings than Biosig Technologies. Shoulder Innovations is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,411.83	-$462.77M	-$9.71	N/A
Shoulder Innovations	$47.32M	9.27	-$40.36M	-$166.96	N/A

In the previous week, Shoulder Innovations had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 3 mentions for Shoulder Innovations and 2 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 0.47 beat Shoulder Innovations' score of 0.41 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shoulder Innovations	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Biosig Technologies beats Shoulder Innovations on 8 of the 15 factors compared between the two stocks.

Get Biosig Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEX vs. The Competition

Export

Metric	Biosig Technologies	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$194.53M	$3.13B	$4.46B	$12.56B
Dividend Yield	N/A	N/A	17.12%	6.64%
P/E Ratio	-0.10	20.07	23.49	24.55
Price / Sales	4,411.83	334.15	167.68	98.03
Price / Cash	N/A	8.98	35.72	58.15
Price / Book	1.17	5.79	13.25	6.45
Net Income	-$462.77M	$7.39M	$113.80M	$336.71M
7 Day Performance	31.16%	2.20%	1.45%	2.55%
1 Month Performance	-18.08%	-1.90%	-2.29%	0.32%
1 Year Performance	N/A	-40.02%	11.24%	25.76%

Biosig Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEX Biosig Technologies	1.9697 of 5 stars	$0.97 -9.3%	$8.00 +724.1%	N/A	$194.53M	$40K	N/A	50	News Coverage
BWAY Brainsway	3.2524 of 5 stars	$15.17 +4.8%	$16.00 +5.5%	+135.6%	$581.07M	$52.22M	43.34	120	Positive News Analyst Forecast
NPCE NeuroPace	2.2093 of 5 stars	$16.53 +0.4%	$18.83 +13.9%	+50.5%	$561.52M	$99.99M	N/A	170	Positive News
CLPT ClearPoint Neuro	2.0771 of 5 stars	$19.43 +5.1%	$23.00 +18.4%	+66.3%	$554.22M	$40.61M	N/A	110	News Coverage Insider Trade
KIDS OrthoPediatrics	3.2605 of 5 stars	$20.08 -1.1%	$24.44 +21.7%	-11.7%	$521.41M	$236.35M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STEX) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biosig Technologies (STEX) Competitors

STEX vs. BWAY, NPCE, CLPT, KIDS, and SI

How does Biosig Technologies compare to Brainsway?

Summary

How does Biosig Technologies compare to NeuroPace?

Summary

How does Biosig Technologies compare to ClearPoint Neuro?

Summary

How does Biosig Technologies compare to OrthoPediatrics?

Summary

How does Biosig Technologies compare to Shoulder Innovations?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biosig Technologies (STEX) Competitors

STEX vs. BWAY, NPCE, CLPT, KIDS, and SI

How does Biosig Technologies compare to Brainsway?

Does the media refer more to STEX or BWAY?

Do institutionals and insiders have more ownership in STEX or BWAY?

Is STEX or BWAY more profitable?

Which has higher valuation and earnings, STEX or BWAY?

Do analysts rate STEX or BWAY?

Which has more risk & volatility, STEX or BWAY?

Summary

How does Biosig Technologies compare to NeuroPace?

Do analysts recommend STEX or NPCE?

Is STEX or NPCE more profitable?

Which has better earnings & valuation, STEX or NPCE?

Does the media favor STEX or NPCE?

Which has more risk and volatility, STEX or NPCE?

Do institutionals & insiders believe in STEX or NPCE?

Summary

How does Biosig Technologies compare to ClearPoint Neuro?

Does the media favor STEX or CLPT?

Do analysts recommend STEX or CLPT?

Which has more risk & volatility, STEX or CLPT?

Do institutionals and insiders hold more shares of STEX or CLPT?

Is STEX or CLPT more profitable?

Which has preferable valuation and earnings, STEX or CLPT?

Summary

How does Biosig Technologies compare to OrthoPediatrics?

Do analysts rate STEX or KIDS?

Does the media favor STEX or KIDS?

Do insiders & institutionals believe in STEX or KIDS?

Which has more risk & volatility, STEX or KIDS?

Which has stronger valuation & earnings, STEX or KIDS?

Is STEX or KIDS more profitable?

Summary

How does Biosig Technologies compare to Shoulder Innovations?

Is STEX or SI more profitable?

Do insiders & institutionals have more ownership in STEX or SI?

Do analysts rate STEX or SI?

Which has preferable earnings and valuation, STEX or SI?

Does the media prefer STEX or SI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools